Real world study of Halaven in breast cancer published in Advances in Therapy – Eisai

Eisai announced results from a real-world study assessing treatment patterns and clinical outcomes with Halaven (eribulin mesylate) injection as a third-line therapy or greater in patients with metastatic breast cancer (mBC), including the triple-negative breast cancer (TNBC) subtype. The median age of patients was 59 years at initiation of Halaven therapy, and 61% of the patients had Eastern Cooperative Oncology Group (ECOG) status 0 or 1. Within the overall mBC cohort, 50% (n=256) had TNBC. A greater proportion of patients with TNBC were treated with Halaven in the 3rd line (87.9%) compared with the overall patient cohort (78%), with the remainder treated in the 4th line or later.

At the time of data cut-off, 96.9% (n=497) in the overall patient cohort and 96.9% (n=248) in the TNBC subgroup had discontinued Halaven treatment. Of the patients who discontinued treatment with Halaven, disease progression was reported as the main reason for 78.1% and 84.3% of patients in the overall cohort and TNBC subtype, respectively. In the overall mBC cohort, median PFS was 6.1 months (95% CI: 5.8-6.6).

In the TNBC subgroup, median PFS was 5.8 months (95% CI: 5.1-6.4). Median OS was 10.6 months (95% CI: 9.9-11.7) in the overall mBC cohort, and 9.8 months (95% CI: 8.6-11.0) in the TNBC subgroup. In the overall mBC cohort, ORR was 54.4% (95% CI: 50.1-58.7), and 55.1% (95% CI: 49.0-61.2) in the TNBC subgroup. In the overall mBC cohort, CBR was 56.7% (95% CI: 52.4-61.0), and 57.4% (95% CI: 51.4-63.5) in the TNBC subgroup. These data were recently published in Advances in Therapy.

See: “Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States” Sarah S. Mougalian et al. Advances in Therapy volume 38, pages 2213–2225 (2021) https://link.springer.com/article/10.1007/s12325-020-01613-6#Fig1